Belief BioMed

Executive Summary

Belief BioMed is a Shanghai-based gene therapy company founded in 2019, dedicated to developing curative treatments for rare genetic diseases and other serious conditions using adeno-associated virus (AAV) vectors. The company's platform aims to deliver therapeutic genes with high precision, addressing significant unmet medical needs. Currently in Phase 2 clinical development, Belief BioMed focuses on advancing its lead product candidate through proof-of-concept trials while expanding its pipeline of AAV-based therapies. With a workforce of 200-500 employees, the company is positioned as a key player in China's burgeoning gene therapy landscape, leveraging local manufacturing and regulatory expertise to expedite development. The company's strategy includes targeting both monogenic disorders and more prevalent conditions where gene therapy can offer transformative benefits. Belief BioMed's progress in the clinic and its robust AAV engineering capabilities suggest strong potential for near-term value inflection, pending successful data readouts and regulatory milestones. The company benefits from China's favorable regulatory environment for innovative therapies and a growing rare disease patient population. Continued investment in R&D and strategic collaborations will be critical to navigating the competitive landscape and achieving commercial success.

Upcoming Catalysts (preview)

• H2 2026Phase 2 clinical data readout for lead AAV-based candidate55% success
• Q1 2027IND acceptance for next-generation gene therapy program70% success
• Q4 2026Series C or partnership financing to support pipeline expansion60% success